10
Jun
2021

Biogen’s Alzheimer’s Controversy, Cytokine Startups Reload, and Vaccines Beat Variants

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Maze Bounces Back, TSLP Investment Surges, & Biosecure Breather
AlphaFold3 Dazzles, a Gene Therapy for Deafness, & Pfizer’s New Strategist
Novartis Doubles Down on Radiopharma, Activation Lethality and FTC Nastygrams
Day One’s Home Run, Big Pharma’s Missed Opportunity, and Tessier-Lavigne Rides Again